Mitochondrial peptides

Two peptides, two opposite entry points to mitochondrial biology

Mitochondria are the metabolic engines of eukaryotic cells — the site of oxidative phosphorylation, the source of most cellular ATP, and increasingly recognised as active signalling hubs that communicate with the rest of the cell. Two peptides in this catalog engage mitochondrial biology from opposite conceptual directions. MOTS-c is a 16-amino-acid peptide encoded within the mitochondrial 12S ribosomal RNA gene — the peptide itself is a product of the mitochondrial genome, one of a young class called mitochondrial-derived peptides (MDPs). It functions as a retrograde signal from the mitochondrion outward. SS-31 (elamipretide) is a synthetic tetrapeptide designed at Cornell that concentrates against the electrical gradient into the inner mitochondrial membrane, where it binds cardiolipin — the phospholipid that stabilises cristae architecture. One peptide is genomically native to mitochondria; the other is a synthetic small molecule that structurally targets them. Together they illustrate why mitochondrial biology has become such an active area of peptide pharmacology.

MOTS-c and the retrograde-signal reframing

For most of the history of cell biology, the mitochondrion was regarded as an obedient organelle that carried out the nuclear genome's instructions — the flow of information ran from nucleus outward. The discovery of MOTS-c by Lee, Cohen and colleagues at USC (Cell Metabolism 2015) proposed something new: the mitochondrion also sends signals back the other way. MOTS-c is encoded by an open reading frame within the mitochondrial 12S ribosomal RNA gene, translated, exported from the mitochondrion, and shown to activate AMP-activated protein kinase (AMPK) in skeletal muscle. AMPK activation drives glucose-uptake improvements, improves insulin sensitivity, and — in aged mice — improves running capacity and skeletal-muscle metabolism (Reynolds Nature Communications 2021, the 'exercise-mimetic' paper). This is retrograde signalling: the mitochondrion sending a metabolic message to the rest of the cell. The reframing changed how endocrinologists think about mitochondria — not just as ATP factories but as active participants in cellular communication.

SS-31 and cardiolipin — the phospholipid target

SS-31 (elamipretide) approaches mitochondrial biology from a completely different angle: as a synthetic tetrapeptide (D-Arg-2',6'-dimethyl-Tyr-Lys-Phe-NH2) designed to concentrate in the inner mitochondrial membrane. Hazel Szeto and Peter Schiller at Cornell developed the compound in the early 2000s based on a specific observation about the inner mitochondrial membrane's electrochemistry. That membrane carries a large negative charge and contains cardiolipin — a signature phospholipid found essentially nowhere else. A small peptide with the right pattern of positive charges and aromatic residues would concentrate against the electrical gradient into the exact place where mitochondria run their energy machinery. SS-31 accumulates roughly 1000-fold in the inner membrane relative to cytoplasm. Once there it binds cardiolipin, stabilising cristae architecture and preserving the assembly of electron-transport-chain supercomplexes. That structural stabilisation is the mechanistic basis for its Barth syndrome approval — Barth is an X-linked disorder of the cardiolipin remodelling enzyme tafazzin, and elamipretide rescues the malformed cardiolipin-dependent structures.

The evidence gap between mouse and human

Both compounds share a structural feature of their evidence bases worth naming: strong preclinical work followed by narrower or absent phase-3 human trial validation. For MOTS-c, the mouse-model work is striking — the Reynolds 2021 exercise-mimetic paper in aged mice is genuinely eye-catching. Human evidence is dominated by circulating-level correlational studies showing that endogenous MOTS-c is lower in aged, obese and diabetic populations. Those correlations are consistent with the preclinical mechanism story but do not demonstrate that giving exogenous MOTS-c to humans reverses those conditions. No phase-2 or phase-3 interventional trial of exogenous MOTS-c has been published. For SS-31, the clinical development story is real: TAZPOWER and its extension in Barth syndrome supported an FDA approval as Forzinity. But the broader mitochondrial-medicine ambitions — primary mitochondrial myopathy (MMPOWER-3), acute cardiac ischaemia-reperfusion (EMBRACE STEMI, MEND2) — have produced mixed to negative results. Extrapolating from the Barth syndrome approval to general 'mitochondrial rejuvenation' claims runs beyond the actual evidence.

Why the mitochondrial-peptide space is expanding

The academic interest in mitochondria-directed peptides has been growing steadily, driven by two convergent recognitions. First, mitochondrial dysfunction is implicated in a widening range of age-related and metabolic diseases — from neurodegeneration to sarcopenia to cardiovascular disease to age-related macular degeneration. Second, the mitochondrial membrane's specific electrochemical and phospholipid environment offers a genuinely tractable pharmacological target for peptides. Additional mitochondrial-derived peptides beyond MOTS-c (humanin, SHLPs 1–6) are now characterised and studied. Additional Szeto-Schiller peptide analogues have been developed. The category is young enough that its future clinical translation is genuinely uncertain, but the mechanistic tractability — a specific membrane with a specific phospholipid that responds to specific peptide chemistry — is what makes the space interesting rather than merely aspirational.

Common questions

References

• The Mitochondrial-Derived Peptide MOTS-c Promotes Metabolic Homeostasis and Reduces Obesity and Insulin Resistance· Lee C, Zeng J, Drew BG, et al. · 2015
• MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis· Reynolds JC, Lai RW, Woodhead JST, et al. · 2021
• Mitochondria-targeted peptide antioxidants — the Szeto-Schiller series and cardiolipin binding as a therapeutic principle· Szeto HH · 2011
• TAZPOWER — a phase 2/3 randomised placebo-controlled crossover study of elamipretide in Barth syndrome and its open-label extension· Reid Thompson W, Manuel R, Abbruzzese C, et al. · 2021
• Elamipretide binds cardiolipin directly and preserves cristae architecture in kidney ischaemia-reperfusion· Birk AV, Liu S, Soong Y, et al. · 2013

Links open external, peer-reviewed sources. Healthy Mango does not host trial data.